Lumakras Sales A Highlight Of Amgen’s Mixed Q3
Aimovig Down Sequentially And Year-Over-Year
While revenue beat consensus, the company slightly lowered its 2021 guidance due to pandemic impacts, but the closely watched KRAS G12C inhibitor exceeded expectations in its first full quarter.
